Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Alzheimer's plaques reduced by targeting sugar attachment to the BACE1 enzyme

15.01.2015

Researchers at the RIKEN-Max Planck Joint Research Center in Japan have demonstrated that hallmark symptoms of Alzheimer's disease can be reduced when sugars are prevented from binding to one of the key enzymes implicated in the disease.

The new findings, reported in EMBO Molecular Medicine, show that abnormal attachment of a particular sugar to the enzyme BACE1 is a critical factor leading to the formation of Aβ plaques in the brain, and that plaques were reduced and cognitive performance improved when this action was prevented in mice through loss of the enzyme GnT-III. In doing so, this work has revealed a novel mechanism for Alzheimer's disease development, potentially opening the way to a new approach for treatment.


Immunostaining of Aβ plaques showed that while the normal mouse model for Alzheimer's disease displayed numerous Aβ plaques (left, black arrows), the number of plaques was significantly reduced when these mice lacked the GnT-III enzyme (right). Scale bar, 300 μm.

Credit: RIKEN

A major factor contributing to Alzheimer's disease is the formation of pathogenic Aβ plaques in the brain when the molecule APP is abnormally cut by the enzyme BACE1, producing Aβ. Because of this, developing drugs that prevent BACE1 from cleaving APP is a central focus of Alzheimer's research. A major stumbling block in these efforts however, is finding a way to do this without disturbing vital processes in the brain and body that are regulated by normal BACE1 activity.

Through a series of experiments, researchers led by Yasuhiko Kizuka, Shinobu Kitazume, and Naoyuki Taniguchi at RIKEN, in collaboration with Tamao Endo and Shigeo Murayama at the Tokyo Metropolitan Institute of Gerontology, showed that much of the BACE1 found in the brains of Alzheimer's disease patients is modified by the attachment of a particular sugar with the help of the enzyme GnT-III. Hypothesizing that preventing this process would relieve Alzheimer's symptoms, the researchers crossed mice that lacked GnT-III with others that express human APP in the brain. They found that Aβ levels and plaque formation were reduced in these hybrid mice, and that cognitive performance was better.

Next, they showed that eliminating the sugared versions of BACE1 is effective in preventing plaque formation because BACE1 without the sugar is destroyed and cannot interact with APP. Using a difficult procedure called subcellular fractionation, they determined that sugared BACE1 is located near APP within cells. However, if the sugar is not attached to it, it is found further from APP and closer to lysosomes--subcellular structures that degrade unneeded molecules. When they examined the mice that lacked GnT-III, they indeed found lower amounts of BACE1.

They then showed that this approach is highly selective. BACE1 normally cleaves several proteins other than APP, and while mice lacking BACE1 also lack Aβ plaques, they also suffer from many side effects and often do not live longer than 4 weeks. On the other hand, the mice tested by Kizuka and his colleagues are healthy, fertile, and behave normally. When examined, these mice did not exhibit higher levels of other proteins that are normally cleaved by BACE1, showing that targeting GnT-III likely only prevents BACE1 from cleaving APP, and can act to reduce Alzheimer's pathology with potentially few side effects.

This research highlights the importance of glycosylation--the modification of proteins by sugars. Far from being rare, it is the most common way in which protein structure is altered, with more than half of proteins being glycosylated in mammals. Kizuka is excited that perhaps now this process will get the attention and press it deserves. He notes that, "although a sugar change is often considered just a marker for disease or a specific cell type, our team has clearly demonstrated the functional role of a glycan during AD development." He added that, "this work offers a good opportunity for many AD researchers to reconsider the importance of glycosylation."

While knocking out GnT-III is feasible in mice, a drug that inhibits GnT-III in the brain has the potential to be an effective treatment for reducing Aβ plaque formation and cognitive decline in humans. Towards this end, Kizuka and colleagues are using a novel screening procedure in collaboration with the RIKEN Program for Drug discovery and Medical Technology Platforms to search for GnT-III inhibitors.

About RIKEN

RIKEN is Japan's largest research institute for basic and applied research. Over 2500 papers by RIKEN researchers are published every year in leading scientific and technology journals covering a broad spectrum of disciplines including physics, chemistry, biology, engineering, and medical science. RIKEN's research environment and strong emphasis on interdisciplinary collaboration and globalization has earned a worldwide reputation for scientific excellence.

Website: http://www.riken.jp/en/

Find us on Twitter at @riken_en

About the Global Research Cluster

The Global Research Cluster brings together projects in diverse disciplines--ranging from astrophysics to chemical biology--which are based primarily on collaborations with universities, industry, and research institutes outside RIKEN. The Cluster provides strong support and leadership for RIKEN's global collaborations in an era when scientific advances are often achieved by international teams using highly specialized instruments, research resources and talents that may only exist at one location in the world. Projects to be incorporated in the Global Research Cluster are selected according to the quality of the leadership and the project's potential for finding solutions to global-scale problems.

Adam Phillips | EurekAlert!

Further reports about: BACE1 GnT-III RIKEN cognitive performance enzyme importance plaques in the brain proteins sugar

More articles from Life Sciences:

nachricht Researchers develop eco-friendly, 4-in-1 catalyst
25.04.2017 | Brown University

nachricht Transfecting cells gently – the LZH presents a GNOME prototype at the Labvolution 2017
25.04.2017 | Laser Zentrum Hannover e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

NASA's Fermi catches gamma-ray flashes from tropical storms

25.04.2017 | Physics and Astronomy

Researchers invent process to make sustainable rubber, plastics

25.04.2017 | Materials Sciences

Transfecting cells gently – the LZH presents a GNOME prototype at the Labvolution 2017

25.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>